Lan and colleagues applied omalizumab, a humanized recombinant monoclonal antibody against IgE, to manage the complication of hyper-IgE syndrome in an autosomal dominant hyper-IgE syndrome patient [55]. The gene discussed is IGHE; the disease is Autosomal dominant hyper-IgE syndrome.